Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 36.10% is 13% below its 5-year average of 41.30%, around the middle of its 5-year range (-7.03%–58.10%).
9.57% above its 12-month average of 32.95%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 27.89%.
GROSS MARGIN
36.10%
GROSS MARGIN AVG TTM
32.95%
GROSS MARGIN AVG 3Y
38.19%
GROSS MARGIN AVG 5Y
41.30%
GROSS MARGIN AVG 10Y
43.61%
GROSS MARGIN AVG 15Y
42.45%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+9.57%
CURRENT VS 3Y AVG
-5.46%
CURRENT VS 5Y AVG
-12.58%
CURRENT VS 10Y AVG
-17.23%
CURRENT VS 15Y AVG
-14.96%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-12.76%
vs the sector median at left
IceCure Medical Ltd
Market Cap
$3.15M
Gross Margin
36.10%
TTM Avg
32.95%
3Y Avg
38.19%
5Y Avg
41.30%
Market Cap
$3.12M
Gross Margin
92.09%
TTM Avg
93.19%
3Y Avg
96.59%
5Y Avg
97.73%
Market Cap
$3.24M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
50.00%
Market Cap
$3.02M
Gross Margin
0.00%
TTM Avg
-310.04%
3Y Avg
-329.59%
5Y Avg
-274.54%
Market Cap
$3.32M
Gross Margin
16.54%
TTM Avg
-251.00%
3Y Avg
-125.05%
5Y Avg
-78.44%
Market Cap
$2.94M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IceCure Medical Ltd (ICCM) | $3.15M | 36.10% | 32.95% | 38.19% | 41.30% |
| MBody AI Ltd. (MBAI)vs › | $3.17M | 0.00% | 0.00% | 0.00% | 0.00% |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.12M | 92.09% | 93.19% | 96.59% | 97.73% |
| Aethlon Medical, Inc. (AEMD)vs › | $3.24M | 0.00% | 0.00% | 25.00% | 50.00% |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.02M | 0.00% | -310.04% | -329.59% | -274.54% |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.32M | 16.54% | -251.00% | -125.05% | -78.44% |
| Revelation Biosciences, Inc. (REVB)vs › | $2.94M | 0.00% | 0.00% | 0.00% | 0.00% |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | 0.00% | 0.00% | 0.00% | 0.00% |
| Moolec Science S.A. (MLEC)vs › | $3.49M | 34.17% | 21.29% | 6.69% | 5.35% |
| Eocene Ltd. (EOCN)vs › | $3.54M | N/A | N/A | N/A | N/A |
Gross Margin
36.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 27.89% |
| 2026-03-31 | 32.38% |
| 2025-12-31 | 46.91% |
| 2025-09-30 | 32.59% |
| 2025-06-30 | 24.95% |
| 2025-03-31 | 30.07% |
| 2024-12-31 | 47.66% |
| 2024-09-30 | 35.50% |
| 2024-06-30 | 52.42% |
| 2024-03-31 | 36.20% |
| 2023-12-31 | 45.34% |
| 2023-09-30 | -7.03% |
| 2023-06-30 | 46.32% |
| 2023-03-31 | 45.07% |
| 2022-12-31 | 49.09% |
| 2022-09-30 | 26.18% |
| 2022-06-30 | 50.20% |
| 2022-03-31 | 58.10% |
| 2021-12-31 | 46.46% |
| 2021-09-30 | 52.72% |
| 2021-06-30 | 39.87% |
| 2021-03-31 | 65.39% |
| 2020-12-31 | 61.39% |
| 2020-09-30 | 69.45% |
| 2020-06-30 | 62.37% |
| 2020-03-31 | 62.37% |
| 2019-12-31 | 40.66% |
| 2019-09-30 | 40.66% |
| 2019-06-30 | 23.91% |
| 2019-03-31 | 23.91% |
| 2018-12-31 | 36.55% |
| 2018-09-30 | 46.96% |
| 2018-06-30 | 42.61% |
| 2018-03-31 | 42.61% |
| 2017-12-31 | -37.44% |
| 2017-09-30 | 6.77% |
| 2017-06-30 | 40.52% |
| 2017-03-31 | 40.52% |
| 2016-12-31 | -29.02% |
| 2016-09-30 | 44.75% |
| 2016-06-30 | 43.13% |
| 2016-03-31 | 51.05% |
| 2015-12-31 | 32.77% |
| 2015-09-30 | 45.40% |
| 2015-06-30 | 28.60% |
| 2015-03-31 | 38.47% |
| 2014-12-31 | 59.33% |
| 2014-09-30 | 30.10% |
| 2014-06-30 | 46.79% |
| 2014-03-31 | -138.89% |
| 2013-12-31 | -47.10% |
| 2013-09-30 | 42.12% |
| 2013-06-30 | -126.39% |
| 2013-03-31 | -86.63% |
| 2012-12-31 | -129.56% |
| 2012-09-30 | -80.16% |
